Teveten HCT (Eprosartan Mesylate / Hydrochlorothiazide) - Summary

TEVETEN HCT SUMMARY

TEVETEN^® HCT 600/12.5 mg and TEVETEN^® HCT 600/25 mg (eprosartan mesylate-hydrochlorothiazide) combine an angiotensin II receptor (AT₁ subtype) antagonist and a diuretic, hydrochlorothiazide. TEVETEN^® (eprosartan mesylate) is a non-biphenyl non-tetrazole angiotensin II receptor (AT₁) antagonist.

TEVETEN^® HCT is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensives such as calcium channel blockers. This fixed dose combination is not indicated for initial therapy (see DOSAGE AND ADMINISTRATION).

See all Teveten HCT indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Teveten HCT (Eprosartan / Hydrochlorothiazide)

High Blood Pressure (Hypertension) Quiz: Symptoms, Signs & Causes
Source: MedicineNet Facial Nerve Problems Specialty [2017.09.19]
Title: High Blood Pressure (Hypertension) Quiz: Symptoms, Signs & Causes
Category: MedicineNet Quiz
Created: 2/9/2011 12:00:00 AM
Last Editorial Review: 9/19/2017 6:02:11 PM

Pulmonary Hypertension (Symptoms, Treatment Medications, Life Expectancy)
Source: MedicineNet Congenital Heart Disease Specialty [2017.07.26]
Title: Pulmonary Hypertension (Symptoms, Treatment Medications, Life Expectancy)
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 7/26/2017 12:00:00 AM

High Blood Pressure (Hypertension)
Source: MedicineNet Polycystic Ovary Specialty [2017.03.31]
Title: High Blood Pressure (Hypertension)
Category: Symptoms and Signs
Created: 1/15/2014 12:00:00 AM
Last Editorial Review: 3/31/2017 12:00:00 AM

Portal Hypertension
Source: MedicineNet nitroglycerin Specialty [2016.09.06]
Title: Portal Hypertension
Category: Diseases and Conditions
Created: 1/31/2005 12:00:00 AM
Last Editorial Review: 9/6/2016 12:00:00 AM

Picture of Hypertension
Source: MedicineNet betaxolol ophthalmic Specialty [2014.12.09]
Title: Picture of Hypertension
Category: Images
Created: 2/3/2011 12:00:00 AM
Last Editorial Review: 12/9/2014 12:00:00 AM

more news >>

Published Studies Related to Teveten HCT (Eprosartan / Hydrochlorothiazide)

Ambulatory monitoring of systolic hypertension in the elderly: Eprosartan/hydrochlorothiazide compared with losartan/hydrochlorothiazide (INSIST trial). [2010.06]
INTRODUCTION: Systolic hypertension is very common in the elderly and is strongly associated with the risk of cardiovascular and cerebrovascular events. The control of systolic hypertension is difficult and most patients require combination antihypertensive therapy. Few data are available regarding the efficacy of angiotensin II receptor antagonists on systolic hypertension of the elderly. The aim of this double-blind, double-dummy, randomized, parallel-group, multicenter study was to assess the efficacy of eprosartan 600 mg in combination with hydrochlorothiazide (HCTZ) 12.5 mg in comparison with losartan 50 mg in combination with HCTZ 12.5 mg, in reducing blood pressure in elderly patients with grade 2 systolic hypertension who did not optimally respond to eprosartan or losartan monotherapy... CONCLUSION: In this study, eprosartan/HCTZ did not demonstrate to be superior to losartan/HCTZ in reducing ABPM systolic hypertension in the elderly.

Safety and tolerability of eprosartan in combination with hydrochlorothiazide. [2002]
The ideal antihypertensive drug should be effective in reducing blood pressure, but have a low incidence of adverse effects... Therefore, the combination of eprosartan with hydrochlorothiazide can be effectively and safely used in patients not adequately responding to eprosartan monotherapy.

more studies >>

Clinical Trials Related to Teveten HCT (Eprosartan / Hydrochlorothiazide)

Comparison of the Effect of Eprosartan and Eprosartan Mesylate on Blood Pressure in Essential Hypertension [Completed]
Aim of this study is to compare the blood pressure lowering effect of a new drug formulation of eprosartan. Eprosartan belongs to a class of blood pressure lowering agents used worldwide since years with proven efficacy. The new formulation is compared to the currently marketed eprosartan tablet. Equivalent efficacy in blood pressure lowering effects should be demonstrated.

Pharmacokinetic Study in Patients With Chronic Kidney Disease and Healthy Volunteers [Completed]
The purpose of this study is to find out how chemicals in the blood of patients with chronic kidney disease affect how medications are removed from the body. The patient will take one dose of three different drugs, one on each week, for a total of three single doses. The investigators want to find out if these three different medications are affected in different ways by the chemicals in the blood of patients with kidney disease.

The Effect of Eprosartan on Hormones and Kidney Function in Healthy Humans. [Completed]
We, the investigators at Holstebro Hospital, want to test the hypothesis that eprosartan

reduces the activity of the sympathetic nervous system in healthy individuals - during

baseline conditions and after activation of the sympathetic nervous system.

Comparison of Eprosartan/HCT Versus Enalapril/HCT in Hypertensives With Type II Diabetes [Completed]

The Effect of Eprosartan on Hormones and Kidney Function in Patients With Essential Hypertension [Completed]
We, the investigators at Holstebro Hospital, want to test the hypothesis that eprosartan reduces the activity of the sympathetic nervous system in patients with essential

hypertension - during baseline conditions and after activation of the sympathetic nervous

system.

more trials >>